Voyager Therapeutics (VYGR) Total Current Liabilities (2014 - 2026)

Voyager Therapeutics has disclosed Total Current Liabilities across 13 years of filings, most recently posting $17.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $17.5 million, down 56.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.5 million (down 56.6% YoY), and the FY2025 annual result was $26.5 million, down 46.69% from the prior year.
• Total Current Liabilities came in at $17.5 million for Q1 2026 at Voyager Therapeutics, down from $26.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $101.7 million in Q1 2022 to a low of $17.5 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $45.4 million (2023), against an average of $53.3 million.
• Across the five-year window, Total Current Liabilities soared 310.8% in 2022 and sank 80.39% in 2023, its largest moves.
• Voyager Therapeutics' Total Current Liabilities stood at $72.6 million in 2022, then decreased by 11.13% to $64.5 million in 2023, then retreated by 22.82% to $49.8 million in 2024, then tumbled by 46.69% to $26.5 million in 2025, then plunged by 34.24% to $17.5 million in 2026.
• The last three Total Current Liabilities figures came in at $17.5 million (Q1 2026), $26.5 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.